Nature Communications, 8 November ,2024, DOI：https://doi.org/10.1038/s41467-024-53041-7

Non-secreting IL12 expressing oncolytic adenovirus Ad-TD-nsIL12 in recurrent high-grade glioma: a phase I trial

Weihai Ning, Xiao Qian, Louisa Chard Dunmall, Funan Liu, Yuduo Guo, Shenglun Li, Dixiang Song, Deshan Liu, Lixin Ma, Yanming Qu, Haoran Wang, Chunyu Gu, Mingshan Zhang, Yaohe Wang, Shengdian Wang & Hongwei Zhang

Abstract

Malignant glioma is a highly fatal central nervous system malignancy with high recurrence rates. Oncolytic viruses offer potential treatment but need improvement in efficacy and safety. Here we describe a phase I, dose-escalating, single arm trial (ChiCTR2000032402) to study the safety of Ad-TD-nsIL12, an oncolytic adenovirus expressing non-secreting interleukin-12, in patients with recurrent high-grade glioma that connects with the ventricular system. Eight patients received intratumoral treatment via stereotaxis or an Ommaya reservoir, with doses ranging from 5×10⁹ to ×10¹⁰vp. The primary end point was to determine the maximal tolerated dose. Secondary endpoints included toxicity and anti-tumour ability. Minimal adverse events were observed at doses of 5×10⁹ and 1×10¹⁰vp. Grade 3 seizure was observed in two patients from Cohort 3 (5×10¹⁰vp). Therefore, the maximum tolerated dose was determined to be 1×10¹⁰vp. Four patients developed hydrocephalus during follow-up. Among them, symptoms in two patients were relieved after placement of a ventriculo-peritoneal shunt, and the other two only showed ventriculomegaly on MRI scan without neurological deterioration. Complete response (according to Response Assessment in Neuro-Oncology Criteria) in one patient, a partial response in one patient and post-treatment infiltrations of CD4+ and CD8+T cells into the tumour were documented during this trial. In conclusion, Ad-TD-nsIL12 has demonstrated safety and preliminary efficacy in patients with recurrent high-grade glioma.

Article link：https://www.nature.com/articles/s41467-024-53041-7